Nonapeptide-1
Brightening peptide
Also Melanostatine, Melanostatine-5, Melanostatine 5, Nonapeptide 1, Alpha-MSH antagonist peptide
- Evidence
- CAnimal and cell studies
- FDA status
- Cosmetic ingredientas of 2026-10-26
- Route
- Topical
- Studies cited
- 0 human1 animal or cell
A skin-care ingredient sold to fade dark spots and brighten skin. It has been tested only in cells, not in people.
Sold for
Nonapeptide-1 is sold in brightening serums and dark-spot creams as a peptide that stops melanin production at its source.
Studies say
Cell and receptor studies show it competes with alpha-MSH at the MC1R receptor, but no published human trial shows it lightens skin, so the grade is C.
Why grade C. The published work on nonapeptide-1 is receptor and cell culture data showing it blocks the melanocyte-stimulating hormone receptor. There is no published controlled human trial of a nonapeptide-1 skin product in these sources. The cell-level mechanism is plausible; the brightening effect on real skin is undocumented. 13
FDA. Nonapeptide-1 is a cosmetic ingredient. Cosmetic ingredients do not go through FDA drug approval, and no nonapeptide-1 product is approved as a drug for any use. 2
Written from 3 cited sources. Fact-checked 2026-10-27: 9 claims checked, 0 corrected. Last refreshed 2026-10-27. Not physician reviewed.
What this means for you
- What people take it for
- Fading dark spots and brightening skin
- Can a US doctor prescribe it?
- No prescription; it is a cosmetic ingredient.
- Properly tested in people?
- Not properly: lab and cell work only, with no published human trial.
Evidence checklist
- Randomised controlled trial No human trialno
- Human study over 100 people No human datano
- More than one research group Manufacturer data sheet and cell workno
- Clinical outcomes, not surrogate markers No clinical outcomesno
- Human safety data beyond case reports No specific safety reportsno
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Nonapeptide-1 is a synthetic nine-amino-acid peptide designed in the 1990s as an antagonist of alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone that tells pigment cells to make melanin. Its first life was as a laboratory tool for studying melanocortin receptors. Cosmetic suppliers later adopted it as a skin-brightening active, often under the trade name Melanostatine-5. 3
It is not a drug. In the United States a product containing it is regulated as a cosmetic unless it makes drug-type claims, and the FDA does not approve cosmetic ingredients before they reach the market. 2
How it works
When ultraviolet light hits skin, keratinocytes release alpha-MSH, which binds the MC1R receptor on melanocytes and switches on the enzyme cascade that makes melanin. Blocking that pathway is one established route to reducing UV-induced pigmentation. Nonapeptide-1 was designed to occupy MC1R without activating it, so alpha-MSH cannot deliver its signal. Supplier data sheets report it inhibits alpha-MSH-driven signaling at nanomolar concentrations in cultured melanocytes and lowers expression of tyrosinase and related pigment enzymes. 13
What human research shows
No peer-reviewed controlled trial of nonapeptide-1 on human skin appears in these sources. The 2022 study in Advances in Dermatology and Allergology that is often cited for it is a cell-culture study of the alpha-MSH to MC1R pathway, not a trial of the peptide in people. Claims of visible brightening rest on manufacturer testing that has not been published in full. 13
| Study | Model | Finding |
|---|---|---|
| Chen 2022 alpha-MSH to MC1R pathway | Cultured melanocytes under UVA exposure | Blocking alpha-MSH signaling at MC1R reduces UV-induced melanin production, the pathway nonapeptide-1 is designed to interrupt. 1 |
| Supplier receptor data | Receptor binding and melanocyte cell culture (manufacturer data sheet) | Nonapeptide-1 is reported as a competitive alpha-MSH antagonist with nanomolar potency in cell assays. 3 |
Safety
Short peptides applied to skin are generally well tolerated, and no specific adverse effects of nonapeptide-1 have been reported in the sources here. That reflects the absence of data as much as any proof of safety. Whether a topical peptide reaches melanocytes in the basal layer of the epidermis at meaningful concentrations is also unestablished. 23
Questions for your clinician
- Is there a human trial showing it fades dark spots?
- Does a topical peptide reach melanocytes?
- What proven treatments exist for my pigmentation?
Questions people ask
Does nonapeptide-1 lighten dark spots?
The mechanism is plausible, and cell studies support it, but no published human trial shows it does so on skin. Products pairing it with established agents such as niacinamide or tranexamic acid make it hard to tell which ingredient is doing the work. 13
Is nonapeptide-1 the same as Melanostatine-5?
Melanostatine-5 is a trade name for a nonapeptide-1 ingredient sold to cosmetic formulators. The INCI name on product labels is nonapeptide-1. 3
Is it regulated by the FDA?
As a cosmetic ingredient it is regulated but not approved. The FDA can act against unsafe or mislabeled cosmetics after they are on sale, but it does not review ingredients beforehand. A brightening product that claimed to treat a disease would be a drug and would need approval. 2
Citations
- Chen 2022, Adv Dermatol Allergol: effects of tea polyphenols on UVA-induced melanogenesis via inhibition of the alpha-MSH to MC1R pathway doi.org
- FDA: how cosmetics are not FDA-approved but are FDA-regulated fda.gov
- MedChemExpress: nonapeptide-1 data sheet (supplier receptor and cell data) file.medchemexpress.com